FDA Approves First Human Trials of AI-Designed Drug for Parkinson’s Disease
The U.S. Food and Drug Administration (FDA) has officially authorized scientists to use the drug ISM8969 in clinical trials and other human studies. The compound was recently developed using artificial intelligence to combat inflammation and neurodegenerative diseases
ES 
EN